PREVENTION OF THROMBOEMBOLIC DISEASE BY PROPHYLACTIC ANTICOAGULATION
PREVENTION OF THROMBOEMBOLIC DISEASE BY PROPHYLACTIC ANTICOAGULATION
复制标题
DOI：
10.2106/00004623-196749010-00006
复制
发表时间：
1967-01-01
影响因子：
5.3
通讯作者：
DESANCTIS, RW
中科院分区：
文献类型：
--
作者：
HARRIS, WH;SALZMAN, EW;DESANCTIS, RW
一个显着的保护作用，防止血栓栓塞性疾病的发生，证明了在一个对照系列的169个选择性髋关节手术的137例连续患者的预防性抗凝与华法林。70例华法林治疗患者中无肺栓塞发生，血栓性静脉炎仅5例，总发生率7%。未接受华法林治疗的67例患者中发生了7例肺栓塞和23例血栓性静脉炎。4例患者同时发生栓塞和静脉炎。本组血栓栓塞性疾病的总发生率为39%。使用抗凝剂所固有的出血风险的轻微增加并不抵消其在预防血栓栓塞并发症方面的明显优势。除非存在特定禁忌症，否则建议所有接受模具成形术的患者预防性抗凝。
A significant protective effect against the occurrence of thromboembolic disease was demonstrated in a controlled series of 169 elective hip operations in 137 consecutive patients by prophylactic anticoagulation with warfarin. No pulmonary embolism and only 5 cases of thrombophlebitis occurred in the 70 patients treated with warfarin, an over-all incidence of 7%. Seven cases of pulmonary embolism and 23 cases of thrombophlebitis occurred in the 67 patients not treated with warfarin. Four patients had both embolism and phlebitis. The over-all incidence of thromboembolic disease in this group was 39%. The slight increase in risk of bleeding inherent in the use of an anticoagulant does not offset its obvious advantage in preventing thromboembolic complications. Prophylactic anticoagulation is recommended in all patients undergoing mold arthroplasty unless a specific contra-indication is present.